Researchers awarded prize for stem cell research

Article

The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3RS) has awarded its annual prize to a project exploring the use of stem cells for treating glaucoma and other eye diseases.

The UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3RS) has awarded its annual prize to a project exploring the use of stem cells for treating retina diseases and other ocular conditions.

Dr Keith Martin and Thomas Johnson of the University of Cambridge's Centre for Brain Repair in the UK are investigating using stem cells as neuroprotectants in damaged retinas. The team implanted the stem cells into explanted tissue from rats' eyes that had been kept alive in the laboratory instead of transplanting the cells into the retinas of anaesthetized animals, as is the traditional method. Because multiple layers of tissue can be obtained from a single animal, Dr Martin's method reduced the number of animals used in experiments to an eighth.

The £10,000 (approx €11,400) NC3RS prize is sponsored by pharmaceutical company GlaxoSmithKline, and was awarded by Phil Willis MP, Chair of the House of Commons Innovation, Universities, Science and Skills Select Committee, at a ceremony in London. Two highly commended prizes were also awarded.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.